Intellectual Disability in the Elderly

  • Joanna C. Lim
  • Laurel J. Bessey
  • Pallavi Joshi
  • Lisa L. Boyle
Chapter

Abstract

Older adults with intellectual disability (ID) represent a heterogeneous population, including individuals with genetic syndromes along with acquired brain injuries that occur during the developmental period, resulting in intellectual cognitive impairments identified in the developmental period that lead to functional impairments. Over the course of several decades, life expectancy of many individuals with ID has increased due to improved medical and social care, leading to increased challenges for providers and society to address the unique needs of this growing older adult population. Older adults with ID are more likely to have comorbid psychiatric disorders, most commonly affective disorders. Psychiatrists will be increasingly called upon to help optimize behavioral and psychiatric health of older adults with ID. Special considerations also include evaluation and management of comorbid neurocognitive disorders in patients with ID.

Keywords

Intellectual disabilities Mental retardation Fragile X syndrome Down syndrome Rett’s syndrome 

References

  1. 1.
    American Psychiatric Association D-TF. Intellectual disabilities. In: Diagnostic and statistical manual of mental disorders. 5th Ed. DSM-5. Arlington, VA: American Psychiatric Association; 2013. P. 33–41.Google Scholar
  2. 2.
    Bittles AH, Petterson BA, Sullivan SG, Hussain R, Glasson EJ, Montgomery PD. The influence of intellectual disability on life expectancy. J Gerontol A Biol Sci Med Sci. 2002;57(7):M470–2.PubMedCrossRefGoogle Scholar
  3. 3.
    Glasson EJ, Sullivan SG, Hussain R, Petterson BA, Montgomery PD, Bittles AH. Comparative survival advantage of males with Down syndrome. Am J Hum Biol. 2003;15(2):192–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Bigby J, Perez-Stable E. The challenges of understanding and eliminating racial and ethnic disparities in health. J Gen Intern Med. 2004;19(2):201–3.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Fisher K, Kettl P. Aging with mental retardation: increasing population of older adults with MR require health interventions and prevention strategies. Geriatrics. 2005;60(4):26–9.PubMedGoogle Scholar
  6. 6.
    Krinsky-McHale SJ, Silverman W. Dementia and mild cognitive impairment in adults with intellectual disability: issues of diagnosis. Dev Disabil Res Rev. 2013;18(1):31–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Dykens EM. Aging in rare intellectual disability syndromes. Dev Disabil Res Rev. 2013;18(1):75–83.PubMedCrossRefGoogle Scholar
  8. 8.
    Maulik PK, Mascarenhas MN, Mathers CD, Dua T, Saxena S. Prevalence of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil. 2011;32(2):419–36.PubMedCrossRefGoogle Scholar
  9. 9.
    Coppus AM, Schuur M, Vergeer J, et al. Plasma beta amyloid and the risk of Alzheimer’s disease in Down syndrome. Neurobiol Aging. 2012;33(9):1988–94.PubMedCrossRefGoogle Scholar
  10. 10.
    Patja K, Iivanainen M, Vesala H, Oksanen H, Ruoppila I. Life expectancy of people with intellectual disability: a 35-year follow-up study. J Intellect Disabil Res. 2000;44(Pt 5):591–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Crawford DC, Acuna JM, Sherman SL. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med. 2001;3(5):359–71.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Turner G, Webb T, Wake S, Robinson H. Prevalence of fragile X syndrome. Am J Med Genet. 1996;64(1):196–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Coffee B, Keith K, Albizua I, et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet. 2009;85(4):503–14.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Partington MW, Robinson H, Laing S, Turner G. Mortality in the fragile X syndrome: preliminary data. Am J Med Genet. 1992;43(1–2):120–3.PubMedCrossRefGoogle Scholar
  15. 15.
    Centers for Disease Control and Prevention. Down syndrome: data and statistics. Updated October 21, 2014; http://www.cdc.gov/ncbddd/birthdefects/downsyndrome/data.html. Accessed 28 Oct 2016.
  16. 16.
    Janicki MP, Dalton AJ, Henderson CM, Davidson PW. Mortality and morbidity among older adults with intellectual disability: health services considerations. Disabil Rehabil. 1999;21(5–6):284–94.PubMedCrossRefGoogle Scholar
  17. 17.
    Day K. Male mentally handicapped sex offenders. Br J Psychiatry. 1994;165(5):630–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Schupf N, Pang D, Patel BN, et al. Onset of dementia is associated with age at menopause in women with Down’s syndrome. Ann Neurol. 2003;54(4):433–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Seltzer GB, Schupf N, Wu HSA. prospective study of menopause in women with Down’s syndrome. J Intellect Disabil Res. 2001;45(Pt 1):1–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Coppus AM, Evenhuis HM, Verberne GJ, et al. Early age at menopause is associated with increased risk of dementia and mortality in women with Down syndrome. J Alzheimers Dis. 2010;19(2):545–50.PubMedCrossRefGoogle Scholar
  21. 21.
    Evenhuis HM, Theunissen M, Denkers I, Verschuure H, Kemme H. Prevalence of visual and hearing impairment in a Dutch institutionalized population with intellectual disability. J Intellect Disabil Res. 2001;45(Pt 5):457–64.PubMedCrossRefGoogle Scholar
  22. 22.
    Prasher VP. Down syndrome and thyroid disorders: a review. Downs Syndr Res Pract. 1999;6(1):25–42.PubMedCrossRefGoogle Scholar
  23. 23.
    Janicki MP, Davidson PW, Henderson CM, et al. Health characteristics and health services utilization in older adults with intellectual disability living in community residences. J Intellect Disabil Res. 2002;46(Pt 4):287–98.PubMedCrossRefGoogle Scholar
  24. 24.
    Oliver C, Crayton L, Holland A, Hall S, Bradbury J. A four year prospective study of age-related cognitive change in adults with Down’s syndrome. Psychol Med. 1998;28(6):1365–77.PubMedCrossRefGoogle Scholar
  25. 25.
    van Schrojenstein Lantman-de Valk HM, Haveman MJ, Maaskant MA, Kessels AG, Urlings HF, Sturmans F. The need for assessment of sensory functioning in ageing people with mental handicap. J Intellect Disabil Res. 1994;38(Pt 3):289–98.PubMedGoogle Scholar
  26. 26.
    Coppus AM, Evenhuis HM, Verberne GJ, et al. Survival in elderly persons with Down syndrome. J Am Geriatr Soc. 2008;56(12):2311–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Cooper SA. Epidemiology of psychiatric disorders in elderly compared with younger adults with learning disabilities. Br J Psychiatry. 1997;170:375–80.PubMedCrossRefGoogle Scholar
  28. 28.
    Cooper SA. High prevalence of dementia among people with learning disabilities not attributable to Down’s syndrome. Psychol Med. 1997;27(3):609–16.PubMedCrossRefGoogle Scholar
  29. 29.
    Strydom A, Hassiotis A, King M, Livingston G. The relationship of dementia prevalence in older adults with intellectual disability (ID) to age and severity of ID. Psychol Med. 2009;39(1):13–21.PubMedCrossRefGoogle Scholar
  30. 30.
    Haveman M, Perry J, Salvador-Carulla L, et al. Ageing and health status in adults with intellectual disabilities: results of the European POMONA II study. J Intellect Develop Disabil. 2011;36(1):49–60.CrossRefGoogle Scholar
  31. 31.
    Matthews T, Weston N, Baxter H, Felce D, Kerr M. A general practice-based prevalence study of epilepsy among adults with intellectual disabilities and of its association with psychiatric disorder, behaviour disturbance and carer stress. J Intellect Disabil Res. 2008;52(Pt 2):163–73.PubMedGoogle Scholar
  32. 32.
    Blair E, Watson L, Badawi N, Stanley FJ. Life expectancy among people with cerebral palsy in Western Australia. Dev Med Child Neurol. 2001;43(8):508–15.PubMedCrossRefGoogle Scholar
  33. 33.
    Nottestad JA, Linaker OM. Psychiatric health needs and services before and after complete deinstitutionalization of people with intellectual disability. J Intellect Disabil Res. 1999;43(Pt 6):523–30.PubMedCrossRefGoogle Scholar
  34. 34.
    Cooper SA, van der Speck R. Epidemiology of mental ill health in adults with intellectual disabilities. Curr Opin Psychiatry. 2009;22(5):431–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Cooper SA, Smiley E, Morrison J, Williamson A, Allan L. Mental ill-health in adults with intellectual disabilities: prevalence and associated factors. Br J Psychiatry. 2007;190:27–35.PubMedCrossRefGoogle Scholar
  36. 36.
    Kessler RC, Demler O, Frank RG, et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med. 2005;352(24):2515–23.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Deb S, Thomas M, Bright C. Mental disorder in adults with intellectual disability. 2: the rate of behaviour disorders among a community-based population aged between 16 and 64 years. J Intellect Disabil Res. 2001;45(Pt 6):506–14.PubMedCrossRefGoogle Scholar
  38. 38.
    Horner-Johnson W, Drum CE. Prevalence of maltreatment of people with intellectual disabilities: a review of recently published research. Ment Retard Dev Disabil Res Rev. 2006;12(1):57–69.PubMedCrossRefGoogle Scholar
  39. 39.
    Evans E, Bhardwaj A, Brodaty H, Sachdev P, Draper B, Trollor JN. Dementia in people with intellectual disability: insights and challenges in epidemiological research with an at-risk population. Int Rev Psychiatry. 2013;25(6):755–63.PubMedCrossRefGoogle Scholar
  40. 40.
    Ross WT, Olsen M. Care of the adult patient with Down syndrome. South Med J. 2014;107(11):715–21.PubMedCrossRefGoogle Scholar
  41. 41.
    Turk J, Fragile X. syndrome: lifespan developmental implications for those without as well as with intellectual disability. Curr Opin Psychiatry. 2011;24(5):387–97.PubMedCrossRefGoogle Scholar
  42. 42.
    Utari A, Adams E, Berry-Kravis E, et al. Aging in fragile X syndrome. J Neurodev Disord. 2010;2(2):70–6.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Backes M, Genc B, Schreck J, Doerfler W, Lehmkuhl G, von Gontard A. Cognitive and behavioral profile of fragile X boys: correlations to molecular data. Am J Med Genet. 2000;95(2):150–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Hagerman RJ, Hagerman PJ. The fragile X premutation: into the phenotypic fold. Curr Opin Genet Dev. 2002;12(3):278–83.PubMedCrossRefGoogle Scholar
  45. 45.
    Kamenetz F, Tomita T, Hsieh H, et al. APP processing and synaptic function. Neuron. 2003;37(6):925–37.PubMedCrossRefGoogle Scholar
  46. 46.
    Westmark CJ, Malter JS. FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol. 2007;5(3):e52.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Hagerman RJ, Hagerman P. Fragile X-associated tremor/ataxia syndrome—features, mechanisms and management. Nat Rev Neurol. 2016;12(7):403–12.PubMedCrossRefGoogle Scholar
  48. 48.
    Jacquemont S, Hagerman RJ, Hagerman PJ, Leehey MA. Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol. 2007;6(1):45–55.PubMedCrossRefGoogle Scholar
  49. 49.
    Hagerman PJ, Greco CM, Hagerman RJ. A cerebellar tremor/ataxia syndrome among fragile X premutation carriers. Cytogenet Genome Res. 2003;100(1–4):206–12.PubMedCrossRefGoogle Scholar
  50. 50.
    Leehey MA. Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment. J Investig Med. 2009;57(8):830–6.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Berry-Kravis E, Abrams L, Coffey SM, et al. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord. 2007;22(14):2018–30. quiz 2140PubMedCrossRefGoogle Scholar
  52. 52.
    Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet. 2003;72(4):869–78.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Budimirovic DB, Kaufmann WE. What can we learn about autism from studying fragile X syndrome? Dev Neurosci. 2011;33(5):379–94.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Terracciano A, Chiurazzi P, Neri G. Fragile X syndrome. Am J Med Genet C Semin Med Genet. 2005;137c(1):32–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Coppus AM. People with intellectual disability: what do we know about adulthood and life expectancy? Dev Disabil Res Rev. 2013;18(1):6–16.PubMedCrossRefGoogle Scholar
  56. 56.
    Sturgeon X, Gardiner KJ. Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mamm Genome. 2011;22(5–6):261–71.PubMedCrossRefGoogle Scholar
  57. 57.
    Ruparelia A, Pearn ML, Mobley WC. Aging and intellectual disability: insights from mouse models of Down syndrome. Dev Disabil Res Rev. 2013;18(1):43–50.PubMedCrossRefGoogle Scholar
  58. 58.
    Beacher F, Daly E, Simmons A, et al. Brain anatomy and ageing in non-demented adults with Down’s syndrome: an in vivo MRI study. Psychol Med. 2010;40(4):611–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Zigman WB. Atypical aging in Down syndrome. Dev Disabil Res Rev. 2013;18(1):51–67.PubMedCrossRefGoogle Scholar
  60. 60.
    Lai F, Kammann E, Rebeck GW, Anderson A, Chen Y, Nixon RA. APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome. Neurology. 1999;53(2):331–6.PubMedCrossRefGoogle Scholar
  61. 61.
    Burt DB, Aylward EH. Test battery for the diagnosis of dementia in individuals with intellectual disability. Working Group for the Establishment of Criteria for the Diagnosis of Dementia in Individuals with Intellectual Disability. J Intellect Disabil Res. 2000;44(Pt 2):175–80.PubMedGoogle Scholar
  62. 62.
    Aylward EH, Burt DB, Thorpe LU, Lai F, Dalton A. Diagnosis of dementia in individuals with intellectual disability. J Intellect Disabil Res. 1997;41(Pt 2):152–64.PubMedCrossRefGoogle Scholar
  63. 63.
    Evenhuis H, Henderson M, Beange H, Lennox N, Chicoine B. Healthy ageing—adults with intellectual disabilities: physical health issues. J Appl Res Intellect Disabil. 2001;14:175–94.CrossRefGoogle Scholar
  64. 64.
    Heller T, Fisher D, Marks B, Hsieh K. Interventions to promote health: crossing networks of intellectual and developmental disabilities and aging. Disabil Health J. 2014;7(1 Suppl):S24–32.PubMedCrossRefGoogle Scholar
  65. 65.
    Evenhuis HM. Medical aspects of ageing in a population with intellectual disability: III. Mobility, internal conditions and cancer. J Intellect Disabil Res. 1997;41(Pt 1):8–18.PubMedGoogle Scholar
  66. 66.
    Thorpe L. Psychiatric disorders. Print Book: English ed. Philadelphia, PA: Brunner/Mazel; 1999.Google Scholar
  67. 67.
    Chicoine B, McGuire D, Rubin S. Specialty clinic perspectives. Print Book: English ed. Castletown, NY: Hamilton Printing; 1999.Google Scholar
  68. 68.
    Bromley J, Emerson E, Caine A. The development of a self-report measure to assess the location and intensity of pain in people with intellectual disabilities. J Intellect Disabil Res. 1998;42(Pt 1):72–80.PubMedCrossRefGoogle Scholar
  69. 69.
    Walsh KK, Kastner T, Criscione T. Characteristics of hospitalizations for people with developmental disabilities: utilization, costs, and impact of care coordination. Am J Ment Retard. 1997;101(5):505–20.PubMedGoogle Scholar
  70. 70.
    Strydom A, Shooshtari S, Lee L, et al. Dementia in older adults with intellectual disabilities—epidemiology, presentation, and diagnosis. J Policy Pract Intellect Disabil. 2010;7(2):96–110.CrossRefGoogle Scholar
  71. 71.
    Fonseca LM, Navatta AC, Bottino CM, Miotto EC. Cognitive rehabilitation of dementia in adults with Down syndrome: a review of non-pharmacological interventions. Dement Geriatr Cogn Dis Extra. 2015;5(3):330–40.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Häβler F, Thome J, Reis O. Polypharmacy in the treatment of subjects with intellectual disability. J Neural Transm. 2015;122(Supplement 1):93–100.Google Scholar
  73. 73.
    Eady N, Courtenay K, Strydom A. Pharmacological management of behavioral and psychiatric symptoms in older adults with intellectual disability. Drugs Aging. 2015;32(2):95–102.PubMedCrossRefGoogle Scholar
  74. 74.
    Tsiouris JA, Kim SY, Brown WT, Pettinger J, Cohen IL. Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study. J Autism Dev Disord. 2013;43(3):719–31.PubMedCrossRefGoogle Scholar
  75. 75.
    Paton C, Flynn A, Shingleton-Smith A, et al. Nature and quality of antipsychotic prescribing practice in UK psychiatry of intellectual disability services. J Intellect Disabil Res. 2011;55:665–74.PubMedCrossRefGoogle Scholar
  76. 76.
    de Leon J, Greenlee B, Barber J, Sabaawi M, Singh NN. Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. Res Dev Disabil. 2009;30(4):613–69.PubMedCrossRefGoogle Scholar
  77. 77.
    Sabaawi M, Singh NN, de Leon J. Guidelines for the use of clozapine in individuals with developmental disabilities. Res Dev Disabil. 2006;27(3):309–36.PubMedCrossRefGoogle Scholar
  78. 78.
    Sawyer A, Lake J, Lunsky Y, Liu S-K, Desarkar P. Psychopharmacological treatment of challenging behaviours in adults with autism and intellectual disabilities: A systematic review. Res Autism Spectr Disord. July 2014;8(7):803–13.CrossRefGoogle Scholar
  79. 79.
    Cohen D, Raffin M, Canitano R, et al. Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: a Bayesian meta-analysis of efficacy and secondary effects. Res Autism Spectr Disord. 2013;7(1):167–75.CrossRefGoogle Scholar
  80. 80.
    Lott IT, Osann K, Doran E, Nelson L. Down syndrome and Alzheimer disease: response to donepezil. Arch Neurol. 2002;59(7):1133–6.PubMedCrossRefGoogle Scholar
  81. 81.
    Prasher VP, Huxley A, Haque MS. Group DsAS. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer’s disease—pilot study. Int J Geriatr Psychiatry. 2002;17(3):270–8.PubMedCrossRefGoogle Scholar
  82. 82.
    Prasher VP, Adams C, Holder R, Group DSR. Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer’s disease in adults with Down syndrome: open label study. Int J Geriatr Psychiatry. 2003;18(6):549–51.PubMedCrossRefGoogle Scholar
  83. 83.
    Prasher VP, Fung N, Adams C. Rivastigmine in the treatment of dementia in Alzheimer’s disease in adults with Down syndrome. Int J Geriatr Psychiatry. 2005;20(5):496–7.PubMedCrossRefGoogle Scholar
  84. 84.
    Prasher VP, Sachdeva N, Adams C, Haque MS. Rivastigmine transdermal patches in the treatment of dementia in Alzheimer’s disease in adults with Down syndrome-pilot study. Int J Geriatr Psychiatry. 2013;28(2):219–20.PubMedCrossRefGoogle Scholar
  85. 85.
    Hanney M, Prasher V, Williams N, et al. Memantine for dementia in adults older than 40 years with Down’s syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;379(9815):528–36.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Joanna C. Lim
    • 1
  • Laurel J. Bessey
    • 2
  • Pallavi Joshi
    • 3
  • Lisa L. Boyle
    • 4
  1. 1.Veterans Affairs Medical CenterWashingtonUSA
  2. 2.Department of PsychiatryUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA
  3. 3.Hofstra-Northwell School of Medicine-Staten Island University HospitalStaten IslandUSA
  4. 4.William S. Middleton Memorial Veterans HospitalMadisonUSA

Personalised recommendations